de Pontual Laure, Gourdon Geneviève, Tomé Stéphanie
Sorbonne Université, Inserm, Institut de Myologie, Centre de Recherche en Myologie, Paris, France.
Med Sci (Paris). 2021 Nov;37 Hors série n° 1:6-10. doi: 10.1051/medsci/2021182. Epub 2021 Dec 8.
Myotonic dystrophy type 1 (DM1) is a multisystemic neuromuscular disease caused by an abnormal CTG repeat expansion in the 3'UTR region of the DMPK gene. In patients, the CTG repeat size varies from fifty to thousands CTG and usually increases across generations (intergenerational instability) and over time in tissues (somatic instability). Larger expansions are associated with more severe symptoms and a decreasing age of onset. Thus, the larger expansions are often associated with the most severe clinical form of DM1 (congenital form). Our PhD project is to identify new genetic and chemical factors reducing the number of repeats and to better understand the mechanisms underlying instability. To this end, genetic and pharmacological screenings are carried out in a HEK293 cell model allowing the rapid detection of expansions (increase in CTG repeat number) and contractions (decrease in CTG repeat number). The effects of different genes and chemical factors, selected during the screening, on the dynamics of the CTG repeat instability will be studied in a DM1 cell model. The results of our work will provide a better understanding of the mechanisms behind contractions. In addition, the identification of new pharmacological compounds promoting CTG contractions and thus reducing or even reversing the progression of disease will offer new therapeutic prospects for DM1 but also for other triplet repeat diseases.
1型强直性肌营养不良症(DM1)是一种多系统神经肌肉疾病,由DMPK基因3'UTR区域的异常CTG重复序列扩增引起。在患者中,CTG重复序列的大小从50到数千个CTG不等,并且通常在几代人之间(代际不稳定性)以及在组织中随时间推移(体细胞不稳定性)增加。更大的扩增与更严重的症状和发病年龄降低有关。因此,更大的扩增通常与DM1最严重的临床形式(先天性形式)相关。我们的博士项目旨在识别减少重复序列数量的新遗传和化学因素,并更好地理解不稳定性背后的机制。为此,在HEK293细胞模型中进行遗传和药理学筛选,以快速检测扩增(CTG重复序列数量增加)和收缩(CTG重复序列数量减少)。在DM1细胞模型中研究筛选过程中选择的不同基因和化学因素对CTG重复序列不稳定性动态的影响。我们工作的结果将有助于更好地理解收缩背后的机制。此外,鉴定促进CTG收缩从而减少甚至逆转疾病进展的新药理化合物将为DM1以及其他三联体重复疾病提供新的治疗前景。